Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
| ▸ | ATP4A | P20648 | 4/20 | 0.42 |
| ▸ | ATP4B | P51164 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956656 | 0.93 | PRKAB2 (0.49) | TGFBR1MAPK14PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL5956439 | 0.83 | TGFBR1 (0.64) | TGFBR1MAPK14 | |
| SCHEMBL5956501 | 0.80 | TGFBR1 (0.56) | TGFBR1MAPK14 | |
| SCHEMBL5956566 | 0.80 | TGFBR1 (0.52) | TGFBR1MAPK14 | |
| SCHEMBL5919631 | 0.80 | TGFBR1 (0.56) | TGFBR1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5956442 | 0.79 | TGFBR1 (0.59) | TGFBR1MAPK14 | |
| SCHEMBL5907478 | 0.79 | TGFBR1 (0.56) | TGFBR1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5956375 | 0.79 | TGFBR1 (0.54) | TGFBR1MAPK14 | |
| SCHEMBL5956381 | 0.79 | TGFBR1 (0.46) | TGFBR1MAPK14LTA4H | |
| SCHEMBL5956461 | 0.78 | TGFBR1 (0.53) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885PRKAB2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.